改写 Analysis of 298 patients receiving atezolizumab in the IMvigrr210 cohort indicated that the risk score in the response group was significantly lower than that in the non-response group

The findings from the IMvigrr210 cohort involving 298 patients who were treated with atezolizumab revealed that the response group exhibited a significantly reduced risk score compared to the non-response group.